Literature DB >> 28924989

Media attention regarding sudden cardiac death associated with domperidone use does not affect in hospital ECG recording.

Florine Berger1, Selma Saâïd2, Teun van Gelder1,3, Bruno Stricker3,4, Matthijs Becker5, Patricia van den Bemt1.   

Abstract

PURPOSE: In March 2013, regulatory warnings concerning the potential risks of domperidone caused considerable media attention in the Netherlands. The aim of the study was to assess the effect of regulatory warnings and the resulting media hype on the frequency of electrocardiogram (ECG) monitoring of inpatients using domperidone. We also studied the effect on the frequency of prescribing domperidone by physicians.
METHODS: A 2-centre, observational, retrospective cohort study was performed. Inpatients using domperidone in 2 hospitals in the Netherlands during a period of 384 days before and after the media hype were included. The main outcomes were (1) the proportion of domperidone users with ECGs before and/or during domperidone treatment, (2) the proportion of patients with an ECG before and during treatment, and (3) the proportion of patients with an ECG during treatment. Secondary outcome was the proportion of domperidone prescriptions comparing the before- and after-period.
RESULTS: Four hundred twenty-eight patients were included. The main outcomes [respectively (1) relative risk (RR) 1.02, 95% confidence interval (CI), 0.85-1.21; (2) RR 1.06, 95% CI, 0.60-1.85; and (3) RR 1.27, 95% CI, 0.80-2.01) were not different. After stratifying for hospital, no significant differences were found. A statistically significant decrease (RR 0.40, 95% CI, 0.35-0.45) in numbers of prescriptions was found for the university medical centre only.
CONCLUSIONS: No effect of the media hype was found on the intensity of ECG monitoring in domperidone users. In the university medical centre, domperidone prescriptions were reduced.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ECG monitoring; QT prolongation; domperidone; media hype; pharmacoepidemiology; regulatory warnings; sudden cardiac death

Mesh:

Substances:

Year:  2017        PMID: 28924989     DOI: 10.1002/pds.4321

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.

Authors:  Irene Sarosiek; Mark Van Natta; Henry P Parkman; Thomas Abell; Kenneth L Koch; Braden Kuo; Robert J Shulman; Gianrico Farrugia; Madhusudan Grover; Frank A Hamilton; Pankaj J Pasricha; Katherine P Yates; Laura Miriel; Laura Wilson; Goro Yamada; James Tonascia; Richard W McCallum
Journal:  Clin Gastroenterol Hepatol       Date:  2021-06-02       Impact factor: 11.382

2.  Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice.

Authors:  Florine A Berger; Heleen van der Sijs; Matthijs L Becker; Teun van Gelder; Patricia M L A van den Bemt
Journal:  BMC Med Inform Decis Mak       Date:  2020-07-23       Impact factor: 2.796

3.  Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data.

Authors:  Kiyon Rhew; Nayoung Han; Jung Mi Oh
Journal:  Int J Environ Res Public Health       Date:  2019-08-20       Impact factor: 3.390

4.  Exploring the Prescribing Process of Domperidone for Low Milk Supply: A Qualitative Study Among Mothers, IBCLCs, and Family Doctors.

Authors:  Lara A Tauritz Bakker; Liset van Dijk; Patricia M L A van den Bemt
Journal:  J Hum Lact       Date:  2020-10-14       Impact factor: 2.219

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.